aDivision of Early Drug Development for Innovative Therapies, European Institute of Oncology IRCCS

bDepartment of Oncology and Hemato-Oncology, University of Milan, Milan, Italy

cLineberger comprehensive cancer center, University of North Carolina, Chapel hill, North Carolina

dDepartment of Medicine, Division of Hematology-Oncology, Weill Cornell Medicine, New York, New York, USA

Correspondence to Paola Zagami, MD, University of Milan, Department of Oncology and Hemato-Oncology, Lineberger comprehensive cancer center, University of North Carolina, Chapel hill, North Carolina, Division of Early Drug Development for Innovative Therapies, European Institute of Oncology (IEO) IRCCS, Via G. Ripamonti n. 435, Milan 20141, Italy. E-mail: [email protected]